Literature DB >> 11495262

Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong.

C C Leung1, C M Tam, S L Chan, M Chan-Yeung, C K Chan, K C Chang.   

Abstract

SETTING: Revaccination of tuberculin-negative school-children is a regular practice in Hong Kong.
OBJECTIVE: To assess the efficacy of BCG revaccination guided by tuberculin skin testing.
METHOD: A cohort of 303,692 children vaccinated at birth was followed through the tuberculosis notification register for the development of active disease. The percentage of cohort who participated in the BCG revaccination program during primary school was estimated from the vaccination statistics of the Hong Kong Department of Health. The BCG revaccination history of identified cases was ascertained through vaccination cards and clinic records.
RESULTS: A total of 85.2% of the cohort participated in the BCG revaccination programme; 79.7% of the participants were tuberculin-negative and revaccinated; 343 developed tuberculosis after the age of 11; 302 were among the participants in the programme while 41 were not. The tuberculosis incidence was 16.5 and 12.9 per 100,000 person-years for participants and non-participants, respectively (RR 1.28, 95%CI 0.92-1.77). Among the participants, tuberculosis incidence was 12.5 and 32.0/100,000 person-years, respectively, for the tuberculin-negative/BCG revaccinated group and the tuberculin-positive/non-revaccinated group (RR 0.39, 95%CI 0.31-0.49).
CONCLUSION: This study failed to demonstrate any significant difference in the incidence rates of tuberculosis among participants and non-participants in a school BCG revaccination programme. The increased risk for tuberculosis in the tuberculin-positive group does not support the use of the tuberculin testing for detection of immunity conferred by neonatal BCG vaccination.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11495262

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  23 in total

1.  Limited impact of tuberculosis control in Hong Kong: attributable to high risks of reactivation disease.

Authors:  E Vynnycky; M W Borgdorff; C C Leung; C M Tam; P E M Fine
Journal:  Epidemiol Infect       Date:  2007-08-03       Impact factor: 2.451

2.  Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein.

Authors:  Marcus A Horwitz; Günter Harth; Barbara Jane Dillon; Sasa Maslesa-Galic
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+ and IGRA- Indian adults.

Authors:  Srabanti Rakshit; Asma Ahmed; Vasista Adiga; Bharath K Sundararaj; Pravat Nalini Sahoo; John Kenneth; George D'Souza; Wesley Bonam; Christina Johnson; Kees Lmc Franken; Tom Hm Ottenhoff; Greg Finak; Raphael Gottardo; Kenneth D Stuart; Stephen C De Rosa; M Juliana McElrath; Annapurna Vyakarnam
Journal:  JCI Insight       Date:  2019-12-19

4.  Tuberculin response in BCG vaccinated schoolchildren and the estimation of annual risk of infection in Hong Kong.

Authors:  C C Leung; W W Yew; C M Tam; C K Chan; K C Chang; W S Law; S N Lee; M Y Wong; K F Au
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

5.  Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.

Authors:  Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson
Journal:  Vaccine       Date:  2014-05-09       Impact factor: 3.641

6.  Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.

Authors:  Ming Zhang; Chunsheng Dong; Sidong Xiong
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

7.  Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guérin.

Authors:  H Martin Vordermeier; Shelley G Rhodes; Gillian Dean; Nilu Goonetilleke; Kris Huygen; Adrian V S Hill; R Glyn Hewinson; Sarah C Gilbert
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

8.  Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination.

Authors:  B M Buddle; D N Wedlock; N A Parlane; L A L Corner; G W De Lisle; M A Skinner
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  The value of counting BCG scars for interpretation of tuberculin skin tests in a tuberculosis hyperendemic shantytown, Peru.

Authors:  M Saito; C T Bautista; R H Gilman; A Bowering; M Z Levy; C A Evans
Journal:  Int J Tuberc Lung Dis       Date:  2004-07       Impact factor: 2.373

10.  Immunological memory transferred with CD4 T cells specific for tuberculosis antigens Ag85B-TB10.4: persisting antigen enhances protection.

Authors:  Darragh Duffy; Amina Dawoodji; Else Marie Agger; Peter Andersen; Jürgen Westermann; Eric B Bell
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.